Prime
Blake Michael Prime, Sharnbrook GB
Patent application number | Description | Published |
---|---|---|
20090304904 | Frozen confection - A frozen confection product having a thickness of less than 40 mm, and comprising from 25 to 70 wt % of transparent ice particles having a mean size of from 2 to 30 mm is provided. A process for producing the frozen confection is also provided. | 12-10-2009 |
Danielle K. Prime, Gnangara AU
Patent application number | Description | Published |
---|---|---|
20100215797 | Treatment of Human Milk - Method for heat treatment of human milk, wherein the milk is kept at an elevated temperature in a pasteurising step. Removal of bacterial constituents and/or viral constituents can be effected if an elevated temperature in the narrow range of 57-61° C. is applied during a time span in the range of 5-60 minutes, with the proviso that for temperatures above 60° C. the milk is kept at this temperature for less than 30 minutes. | 08-26-2010 |
20140193555 | Treatment of human milk - The invention provides a method for pasteurizing mother's milk that maximizes the retention of immunologically active constituents of the milk while removing effective amounts of dangerous bacteria and viruses. This includes a pasteurization temperature in the range of 56° C. to 61° C. at which the milk is held during pasteurization for a time span. The invention also provides a method for adjusting the fat content of mother's milk. This includes a method to standardize the energy content of mother's milk by adjusting the fat content by separating the milk contents, as by centrifuging, into at least fat and skim milk layers. The volume of skim milk is adjusted to meet the desired fat concentration, i.e., skim is removed to increase, or added to decrease. | 07-10-2014 |
David Prime, Hertfordshire GB
Patent application number | Description | Published |
---|---|---|
20100000529 | MANIFOLD FOR USE IN MEDICAMENT DISPENSER - There is provided a manifold for use in a medicament dispenser device for the delivery of medicament powder from an open blister pocket of a blister pack. The manifold comprises a body, the body defining a chimney having a chimney inlet and a chimney exit for directing airflow from the chimney inlet to the chimney exit; the body further defining a chamber having a chamber inlet and a chamber exit. The chimney exit and said chamber inlet lie side-by-side each other such that when said open blister pocket of said blister pack is positioned adjacent thereto said airflow may be directed from the chimney exit to the chamber inlet via the open blister pocket to entrain said medicament powder and enable transport thereof in the airflow from the chamber inlet to said chamber outlet. The manifold is arranged such as to delay the emptying of the medicament powder from the blister pocket. | 01-07-2010 |
David Prime, Sandy GB
Patent application number | Description | Published |
---|---|---|
20100260247 | DIGITAL INTERCOM NETWORK OVER DC-POWERED MICROPHONE CABLE - A digital intercom system provides DC power and multi-channel bidirectional digital communications over existing cabling such as microphone cabling used in analog intercom networks. Three or more conductors in the cabling are used for both transmitting and receiving digital signals and carrying DC power. The digital intercom system includes digital user stations and a digital master station which can be used to retrofit an existing analog intercom network or deployed in a new network. User stations can be connected to the cabling via drop cables which do not use active electronic components. The master station routes digital audio and control data packets in three or more channels based on respective network addresses of the user stations to provide point-to-point, point-to-multi-point, and party line communications among the user stations. Sessions and groups can be configured which define talker and listener user stations. | 10-14-2010 |
20130064360 | DIGITAL INTERCOM NETWORK OVER DC-POWERED MICROPHONE CABLE - A digital intercom system provides DC power and multi-channel bidirectional digital communications over existing cabling such as microphone cabling used in analog intercom networks. Three or more conductors in the cabling are used for both transmitting and receiving digital signals and carrying DC power. The digital intercom system includes digital user stations and a digital master station which can be used to retrofit an existing analog intercom network or deployed in a new network. User stations can be connected to the cabling via drop cables which do not use active electronic components. The master station routes digital audio and control data packets in three or more channels based on respective network addresses of the user stations to provide point-to-point, point-to-multi-point, and party line communications among the user stations. Sessions and groups can be configured which define talker and listener user stations. | 03-14-2013 |
Emma Louise Prime, Victoria AU
Patent application number | Description | Published |
---|---|---|
20120018387 | METHOD FOR CONTROLLING WATER EVAPORATION - The present invention relates to a method for controlling evaporation from a body of water. The method of the invention uses a water insoluble compound and a water soluble polymer, which interact with each other by non-covalent bonding interactions. | 01-26-2012 |
Michael Prime, Abingdon GB
Patent application number | Description | Published |
---|---|---|
20120302539 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF - Certain compounds and pharmaceutically acceptable salts are provided herein. Also provided are pharmaceutical compositions comprising at least one compound or pharmaceutically acceptable salt therein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain disease states responsive to the inhibition of transglutaminase TG2 activity are described. These disease states include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound or pharmaceutically acceptable salt thereof as a single active agent or administering at least one compound or pharmaceutically acceptable salt thereof in combination with one or more other therapeutic agents. | 11-29-2012 |
20150057238 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF - Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity. | 02-26-2015 |
Michael Prime, Oxon GB
Patent application number | Description | Published |
---|---|---|
20090221599 | PHTHALAZINONE PYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS - Objects of the present invention are the compounds of formula I | 09-03-2009 |
20100292247 | HETEROCYCLYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS - Objects of the present invention are the compounds of formula I, their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above compounds, medicaments containing them and their manufacture, as well as the use of the above compounds in the control or prevention of illnesses such as cancer. | 11-18-2010 |
Michael Prime, Oxfordshire GB
Patent application number | Description | Published |
---|---|---|
20130116216 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF - Certain compounds and pharmaceutically acceptable salts are provided herein. Also provided are pharmaceutical compositions comprising at least one compound or pharmaceutically acceptable salt therein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain disease states responsive to the inhibition of transglutaminase TG2 activity are described. These disease states include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound or pharmaceutically acceptable salt thereof as a single active agent or administering at least one compound or pharmaceutically acceptable salt thereof in combination with one or more other therapeutic agents. | 05-09-2013 |
20140329795 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF - Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity. | 11-06-2014 |
20140329816 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF - Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity. | 11-06-2014 |
Neil Prime, Auckland NZ
Patent application number | Description | Published |
---|---|---|
20100170509 | BREATHING ASSISTANCE APPARATUS - A pressure regulating device includes a housing having a gases inlet adapted to in use be in fluid communication or integrated with a breathing assistance apparatus which conveys gases to an infant or a neonate requiring breathing assistance, an outlet adapted to be in use in fluid communication with said infant, and an aperture which enables the venting of a portion of gases that in use are passing through the housing from the inlet to the outlet. A tube inlet on the housing is adapted to receive a surfactant delivery device therethrough to enable administration of surfactant to the infant or neonate. A sealing mechanism seals around the surfactant delivery device and is adapted to normally fluidically seal the tube inlet and in use allow the surfactant delivery device to pass through the tube inlet. | 07-08-2010 |
Oliver Prime, Cambridge GB
Patent application number | Description | Published |
---|---|---|
20100238243 | FILTER FOR INK SUPPLY SYSTEM - An ink supply system for an ink jet printer has an ink circuit including a plurality of circuit components and fluid paths for conveying ink between components. A manifold defining the fluid paths and a plurality of ports in fluid communication with the paths. A filter module is provided adjacent to the manifold and comprises a housing that houses at least a first filter, the housing having an inlet and an outlet. The filter module is connected to the manifold such that at least one of the inlet or the outlet is in fluid communication with one of the plurality of ports on the manifold. The filter module may comprise an ink filter and a solvent filter. A second ink filter may be provided upstream of a pump. The modular nature of the filter makes for easy assembly, service and repair. It also provides for improved printer reliability. | 09-23-2010 |
20110085009 | INK SUPPLY SYSTEM - An ink supply system for an ink jet printer, particularly a continuous ink jet printer, has a manifold assembly of two parts that are brought together at interfacing surfaces. At least one of the surfaces has a plurality of ink flow channels for conveying ink around an ink circuit between components. The other of the interfacing surfaces is configured to close and seal the channels. A plurality of ports is provided in fluid communication with the channels, the circuit components being connectable to the ports. The manifold assembly provides for a compact and neat arrangement free of many tubes and pipes. The lower number of connections significantly reduces the risk of leakage. | 04-14-2011 |
Owen James Prime, Chatswood AU
Patent application number | Description | Published |
---|---|---|
20120278341 | DOCUMENT ANALYSIS AND ASSOCIATION SYSTEM AND METHOD - Methods and systems for indexing a plurality of documents, each document comprising a text portion, the method parses the text portion of each of the plurality of documents to form a plurality of respective local document indexes each associated with a respective document, and stores the local document index in a database, Each local document index has a plurality of local text terms and a local weighting associated with each text term From the plurality of local document indexes, forming a global document index associated with each global text term. The global weighting is determined with respect to a parameter associated with a reference global text term. Also, methods and systems for analyzing a text portion, retrieving documents from a database relevant to the text portion and for refining the results of a search are disclosed. | 11-01-2012 |
Solen Prime, Le Mans FR
Patent application number | Description | Published |
---|---|---|
20140261482 | Method of Reducing Tobacco-Specific Nitrosamines - A method for reducing the tobacco specific nitrosamines (TSNAs) in tobacco and tobacco smoke is provided. The tobacco is combined with a solvent to form a soluble extracts fraction and an insoluble residue fraction. The soluble extracts fraction is contacted with a nitrosamine-reducing material to provide a soluble extracts fraction having a reduced level of TSNAs. The nitrosamine-reducing material may comprise a sepiolite. The insoluble residue fraction is contacted with an alkali extractant to provide an insoluble residue fraction having a reduced level of TSNAs. The alkali extractant may comprise a hydroxide. The soluble extracts fraction having a reduced level of TSNAs and insoluble residue fraction having a reduced level of TSNAs may be recombined to form a reconstituted tobacco product having a reduced level of TSNAs. The TSNAs may be reduced by at least about 30%, such as at least about 40%, such as at least about 50%. | 09-18-2014 |
Terry Prime, Herndon, VA US
Patent application number | Description | Published |
---|---|---|
20120191872 | SYSTEM AND METHOD FOR ASSURING SERVICE OF SESSIONS CREATED BY SESSION INITIATION PROTOCOL (SIP) IN AN INTERNET PROTOCOL NETWORK - A system for assuring service of SIP sessions in an internet protocol (IP) network, includes a plurality of probes connected to a plurality of network operators at a plurality of locations in the network and generating a plurality of event streams, and a service assurance manager which performs pattern matching to determine if an event pattern in the plurality of event streams matches a pre-defined event pattern, updates network data including a network operator data model and network routing characteristics based on a result of the pattern matching, and performs a correction based on the updated network data, the correction including avoiding a problematic portion of the network by one of session steering, session routing and session throttling. | 07-26-2012 |